A systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for diffuse malignancy peritoneal mesothelioma

Annals of Oncology

Volumn 18, Issue 5, 2007, Pages 827-834

  Yan, T D ^a   Welch, L ^b   Black, D ^c   Sugarbaker, Paul H ^a,d  

^a WASHINGTON CANCER INSTITUTE   (United States)

^b The Center for Construction Research and Training   (United States)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d NONE   (United States)

Author keywords

Asbestos; Cisplatin; Cytoreductive surgery; Doxorubicin; Intraperitoneal chemotherapy; Peritoneal mesothelioma; Peritonectomy

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DOXORUBICIN; FLUOROURACIL; MITOMYCIN C; PACLITAXEL; THIOSULFATE;

CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CYTOREDUCTIVE SURGERY; DIFFUSE MALIGNANT PERITONEUM MESOTHELIOMA; EVIDENCE BASED MEDICINE; HUMAN; MEDICAL LITERATURE; META ANALYSIS; MONOTHERAPY; MORBIDITY; OBSERVATIONAL STUDY; OUTCOMES RESEARCH; OVERALL SURVIVAL; PEER REVIEW; PERIOPERATIVE PERIOD; PERITONEUM MESOTHELIOMA; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITATIVE RESEARCH; REVIEW; SURVIVAL RATE; SURVIVAL TIME; SYSTEMATIC REVIEW; TERTIARY HEALTH CARE;

EID: 34447311107     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdl428     Document Type: Review

References (62)

1. Wagner JC, Sleegs CA, Marchand P. Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province. Br J Int Med 1960; 17: 260-271.
2. McDonald AD, MacDonald JC. Epidemiology of malignant mesothelioma. In Antman K, Aisner J (eds): Asbestos-Related Malignancy. Orlando, FL: Grune & Stratton, 1987; 31-35.
3. Price B. Analysis of current trends in the United States mesothelioma incidence. Am J Epidemiol 1997; 145: 211-218.
4. Scott B, Mulkherjee S, Lake R et al. Malignant mesothelioma, In Hanson H (ed): Textbook of Lung Cancer. London: Martin Dunitz 2000; 273-293.
5. Robinson BWS, Lake RA. Advances in malignant mesothelioma. N Engl J Med 2005; 353: 1591-1603.
6. Miller J, Wynn H. A malignant tumor arising from the endothelium of the pentoneum and producing a mucola ascitic fluid. J Pall Bacteriol 1908; 12: 267.
7. Price B, Ware A. Mesothelioma trends in the Unites States: An update based on surveillance, epidemiology and end results program data from 1973 through 2003. Am J Epidemiol 2004; 159: 107-112.
8. Welch LS, Acherman YIZ, Haile E et al. Asbestos and peritoneal mesothelioma among college-educated men. Int J Occup Environ Health 2005; 11: 254-258.
9. Antman KH, Corson JM, Li FP et al. Malignant mesothelioma following radiation exposure. J Clin Oncol 1983; 1: 695-700.
10. Chahinian AP, Pajak TF, Holland JF et al. Diffuse malignant mesothelioma, Prospective evaluation of 69 patients. Ann Intern Med 1982; 96: 746-755.
11. Riedel RH, Goodman MJ, Moosa AR. Peritoneal malignant mesothelionna in a patient with recurrent peritonitis. Cancer 1981; 48: 134-139.
12. Maurer R, Egloff B. Malignant peritoneal mesothelioma after cholangiography with thorotrast. Cancer 1975; 36: 1381-1385.
13. Peterson JT, Greenberg SD, Buffler PA. Non-asbestos related malignant mesothelioma. Cancer 1984; 54: 951-960.
14. Acherman YIZ, Welch LS, Bromley CM et al. Clinical presentation of peritoneal mesothelioma. Tumori 2003; 89: 269-273.
15. Moertel CG, Peritoneal mesothelioma. Gastroenterology 1972; 631: 346-350.
16. Chailleux E, Dabouis G, Pioche D et al. Prognostic factors in diffuse malignant pleural mesothelioma. A study of 167 patients Chest 1988; 93: 159-162.
17. Antman K, Shemin R, Ryan L et al. Malignant mesothelioma: Prognostic variables in a registry of 180 patients, the Dana-Farber Cancer Institute and Brigham and Women's Hospital experience over two decades, 1965-1985. J Clin Oncol 1988; 6: 147-153.
18. Sridhar KS, Doria R, Raub WA Jr et al. New strategies are needed in diffuse malignant mesothelioma. Cancer 1992; 70: 2969-2979.
19. Markman M, Kelsen D. Efficacy of cisplatin based intraperitoneal chemotherapy as treatment of malignant peritoneal mesothelioma. J Cancer Res Clin Oncol 1992; 118: 547-550.
20. Yates DH, Corrin B, Stidolph PN et al. Malignant mesothelioma in south east England: Clinicopathological experience of 272 cases. Thorax 1997; 52: 507-512.
21. Neumann V, Muller KM, Fischer M. Peritoneal mesothelioma - incidence and etiology. Pathologe 1999; 20: 169-176.
22. Eltabbakh GH, Piver MS, Hempling RE et al. Clinical picture, response to therapy, and survival of women with diffuse malignant peritoneal mesothelioma. J Surg Oncol 1999; 70: 6-12.
23. Sugarbaker PH. Peritonectomy procedures. Ann Sung 1995: 221: 29-42.
24. Katz MH, Barone RM. The rationale of pepoperative intraperitoneal chemotherapy in the treatment of peritoneal surface malignancies. Surg Oncol Clin N Am 2003; 12: 673-688.
25. Sticca RP, Dach BW. Rationale for hyperthermia with intraoperative intraperitoneal chemotherapy agents. Surg Oncol Clin N Am 2003; 12: 689-701.
26. Sugarbaker PH. New standard of care for appendiceal epithelial neoplasms and pseudomyxoma peRItonei syndrome. Lancet Oncol 2006; 7: 69-76.
27. Bryant J, Clegg AJ, Sidhu MK et al. Systematic review of the Sugarbaker procedure for pseudomyxoma peritonei. Br J Surg 2005; 92: 153-158.
28. Glehen O, Kwiatkowski F, Sugarbaker PH et al. Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: A multi-institutional study. J Clin Oncol 2004; 22: 3284-3292.
29. Verwaal VJ, van Ruth S, Witkamp A et al. Long-term survival of peritoneal carcinomatosis of colorectal origin. Ann Surg Oncol 2005; 12: 65-71.
30. Verwaal VJ, van Ruth S, de Bree E et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal origin. J Clin Oncol 2003; 21: 3737-3743.
31. Look M, Chang D, Sugarbaker PH. Long-term results of cytoreductive surgery for advanced and recurrent epithelial ovarian cancers and papillary serous carcinoma of the peritoneum. Int J Gypecol Cancer 2004; 14: 35-41.
32. Armstrong DK, Bundy B, Wenzel L et al. Intraperitoneal cisplatin ano paclitaxel in ovarian cancer. N EngI J Med 2006; 354: 77-79.
33. Sebbag G, Yan H, Shmookler BM et al. Results of treatment of 33 patients with peritoneal mesothelioma. Br J Surg 2000; 87: 1587-1593.
34. Sugarbaker PH, Acherman YIZ, Gonzalez-Moreno S et al. Diagnosis and treatment of peritoneal mesothelioma: The Washington Cancer Institute experience. Semin Oncol 2002; 29: 51-61.
35. Sugarbaker PH, Welch LS, Mohamed F et al. A review of peritoneal mosothelioma at the Washington Cancer Institute. Surg Oncol Clin N Am 2003; 12: 605-621.
36. Yan TD, Popa E, Brun EA et al. Sex difference in diffuse malignant peritoneal mesothelioma. Br J Surg (In press).
37. Yan TD, Brun EA, Carlos AC et al. Prognostic indicators for patients undergoing cytoreductive surgery and perioperative intraperitoreal chemotherapy for diffuse malignant peritoneal mesothelioma. Ann Surg Oncol (In press).
38. Yan TD, Alderman R, Edwards G et al, Morbidity and mortality assessment of cytoreductive surgery and perioperative intraperitoneal chemotherapy for diffuse malignant peritoneal mesothelioma - a prospective study of 70 consecutive cases. Ann Sung Oncol (In press).
39. Yan ID, Yoo D, Sugarbaker PH. Significance of lymph node metastasis in patients with diffuse malignant peritoneal mesothelioma. Eur J Surg Oncol DOI: 10.1016/j.ejso.2006.05.009.
40. Ma GY, Bartlett DL, Reed E et al. Continuous hyperthermic peritoneal perfusion with cispatin for the treatment of peritoneal mosothelioma. Cancer J Sci Am 1997; 3: 174-179.
41. Park BJ, Alexander HR, Libutti SK et al. Treatment of primary peritoneal mesothelioma by continuous hyperthermic peritoneal perfusion (CHPP). Ann Surg Oncol 1999; 6: 582-590.
42. Feldman AL, Libutti SK, Pingpank JF et al. Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy. J Clin Oncol 2003; 21: 4560-4567.
43. Deraco M, Casali P, Inglese MG. Peritoneal mesothelioma treated by induction chemotherapy, cytoreductive surgery and intraperitoneal hyperthermic perfusion. J Surg Oncol 2003; 83: 147-153.
44. Nonaka D, Kusamura S, Baratti D et al. Diffuse malignant mesothelioma of peritoneum: A clinicopathologic study of 35 patients treated locoregionally at a single institution. Cancer 2005; 104 (10): 2181-2188.
45. Deraco M, Nonaka D, Baratti D et al. Prognostic analysis of clinicopathologic factors in 49 patients with diffuse malignant peritoneal mesothelioma treated with cytoreductive surgery and intraperitoneal hyperthermic perfusion. Ann Surg Oncol 2006; 13: 229-237.
46. Glehen O, Mitheux F, Osinsky D et al. Surgery combined with peritonectomy procedures and intraperitoneal chemohyperthermia in abdominal cancers with peritoneal cancinomatosis: A phase II study, J Clin Oncol 2003; 21: 790-806.
47. Brigand C, Monneuse O, Mohamed F et al. Malignant peritoneal mesothelioma treated by cytoreductive surgery and intraperitoneal chemohyperthermia: Results of a prospective study. Ann Surg Oncol 2006; 13: 405-412.
48. Loggie BW, Fleming RA, McQuellon RP et al. Prospective trial for the treatment of malignant peritoneal mesothelioma. Am Surrrg 2001; 67: 999-1003.
49. NHS Centre for Reviews and Dissemination. Undertaking Systemic Reviews of Research on Effectiveness: CRD's Guidance for those Carrying Out or Commissioning Reviews. CRD Report 4, 2nd edition. York, PA: NHS Centre for Reviews and Dissemination 2001.
50. Armour EP, McEachern D, Wang Z et al. Sensitivity of human cells to mild hyperthermia. Cancer Res 1993; 53: 2740-2744.
51. Los G, Smals OAG, van Vogt MJH et al. A rationale for carboplatin treatment and abdominal hyperthermia in cancers restricted to the peritoneal cavity. Cancer Res 1992; 52: 1252-1258.
52. van de Vaart PJ, van der Vange N, Zoetmulder FAN et al. Intraperitoneal cisplatin with regional hyperthermia in advanced ovarian cancer: pharmacokinetics and cisplatin-DNA adduct formation in patients and ovarian cancer cell lines. Eur J Cancer 1998; 34: 148-154.
53. Los G, Sminia P, Wondergem J et al. Optimization of intrapentoneal cisplatin therapy with regional hyperthermia in rats. Eur J Cancer 1991; 27: 472-477.
54. Kuh HJ Jang SH, Wientjes MG et al. Determinants of paclitaxel penetration and accumulation in human solid tumor. J Pharmacol Exp Their 1999; 290: 871-880.
55. Jacquet P, Stephens AD, Averbach AM et al. Analysis of morbidity and mortality in 60 patients with peritoneal carcinomatosis treated by cytoreductive surgery and heated intraoperative intraperitoneal chemotherapy. Cancer 1996; 77: 2622-2629.
56. Stephens AD, Alderman R, Chang D et al. Morbidity and mortality of 200 treatments with cytoreductive surgery and hyperthermic intraoperative intraperitoneal chemotherapy using the Coliseum technique. Ann Surg Oncol 1999; 6: 790-796.
57. Elias D, Blot F, El Otmany A et al. Curative treatment of peritoneal carcinomatosis arising from colorectal cancer by complete resection and intraperitoneal chemotherapy. Cancer 2001; 92: 71-76.
58. Butterworth SA, Panton ONM, Klaassen DJ et al. Morbidity and mortality associated with intraperitoneal chemotherapy for pseudomyxoma peritonei. Am J Sung 2002; 183: 529-532.
59. Glehen O, Osinsky D, Cotte E et al. intraperitoneal chemohyperthermia using a closed abdominal procedure and cytoreductive surgery for the treatment of peritoneal carcinomatosis: Morbidity and mortality analysis of 216 consecutive procedures. Ann Surg Oncol 2003; 10: 863-869.
60. Ahmad SA, Kim J, Sussman JJ et al. Reduced morbidity following cytoreductive surgery and intraperitoneal hyperthermic chermoperfusion. Ann Surg Oncol 2004; 11: 387-392.
61. Yap TD, Haveric N, Carmignani CP et al. Abdominal computed tomography scans in the selection of patients with malignant peritoneal mesothelioma for comprehensive treatment with cytoreductive surgery and perioperative intraperitoneal chemotherapy. Cancer 2005; 103: 839-849.
62. Janne PA, Wozniak AJ, Belani CP et al. Open-label study of pemetrexed alone or in combination with cisplatin for the treatment of patients with peritoneal mesothelioma: Outcomes of an expanded access program. Clin Lung Cancer 2005; 7: 40-46.